INTRODUCTION
Lamotrigine (3,5 -diamino-6-( 2,3 -dichlorophenyll-1,2,4-triazinel is an antiepileptic drug (AEDl that has a broad spectrum of activity. It has been shown to produce a statistically and clinically significant reduction in seizure frequency when evaluated as an add-on therapy in doubleblind, placebo-controlled trials of patients with treatment-resistant epilepsy.' -Ii The efficacy of lamotrig~ne has been shown against partial seizures, with and without secondary generalization.v" and also against tonic-clonic seizures." Efficacy of add-on therapy with lamotrigine has also been shown in a number of open trials."l:l Lamotrigine is well-tolerated;" and there has been no evidence of any cognitive impairment." The most commonly reported side-effect is skin rash, occurring in up to 10% of patients. Beneficial effects on seizure severity!" and mood-" have been observed with lamotrigine, independent of any effect on seizure frequency. The withdrawal of concomitant AEDs in order to obtain lamotrigine monotherapy has been possible in many patients.l'v'" resulting in improved tolerability without loss of seizure control.
Lamotrigine exhibits linear kinetics, with no evidence of autoinduction of metabolism.s?
The elimination of lamotrigine is affected by concomitant AEDs. Enzyme-inducing drugs such as phenytoin and carbamazepine reduce the half-life of lamotrigine to approximately 15 h, while valproate prolongs the half-life to approximately 60 h. Zl The present study was an open trial designed to investigate the safety and efficacy of lamotrigine in patients with poorly controlled seizures at five centres in Portugal. Patients were receiving a range of other AEDs, and the efficacy of lamotrigine when added to different regimens was assessed.
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PATIENTS AND METHODS
PATIENTS
Patients with a diagnosis of epilepsy resistant to AEDs of first choice (appropriate to the type of epilepsy or seizure) were eligible for inclusion in the study. Seizures were classified by the International Classification of Seizures.P and were not complicated by pseudoseizures. To be included, patients had to have experienced at least six seizures in the 3 months preceding the study, or two seizures in the month preceding the study. Patients who had experienced status epilepticus in the 6 months preceding the study, or more than once in the 2 years preceding the study were excluded, as were those with severe organic or psychiatric disease (other than epilepsy) and progressive neurological disease. Women who were pregnant, lactating or at risk of pregnancy were excluded, so that female patients enrolled in the study were post-menopausal, had undergone hysterectomy, oophorectomy or sterilization, or used adequate contraception.
PROCEDURES
At the enrolment visit, physical and neurological examinations were carried out, and vital signs were measured. Routine haematology and blood chemistry assessments were made. Seizure history, types and previous electroencephalogram results were recorded, together with seizure frequency for the previous 3 months, medical history, current AED treatment regimen and an inventory of adverse experiences.
The study was designed to last for 24 months, with patients keeping a daily record of seizure frequency and AED medication taken. Patients were seen by the investigator at the end of months 1, 2, 3, 6, 9, 12, 18 and 24. o Leitiio, MJ Sampaio et al.
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At these visits, physical and neurological examination, vital signs, adverse experiences and daily seizure counts were recorded. The investigator gave a rating of efficacy on a five-point scale of marked improvement, mild improvement, no change, mild deterioration or marked deterioration. If benefits of lamotrigine were seen and it was deemed appropriate by the investigator, concomitant AEDs could be withdrawn after months 3 and 6, in steps according to accepted clinical practice.
CLASSIFICATION OF SEIZURES
Complex partial seizures were classified as follows: Hl. Complex partial seizures with simple partial onset followed by impairment of consciousness, (a) with simple partial features and impaired consciousness, (b) with automatisms; H2. Complex partial seizures with impairment of consciousness at onset, (a) with impairment of consciousness only, (b) with motor, automatic, sensory or psychic features, noted in the International Classification of Epileptic Seizures.s"
EFFICACY ANALYSIS
At each assessment, the investigator gave a rating of efficacy based on the frequency of seizures recorded in the daily diaries kept by the patients. Both overall efficacy and efficacy for the subgroups of patients, grouped according to seizure type and concomitant treatment. were recorded.
STUDY MEDICATION
Lamotrigine tablets or capsules were used at doses of 12.5, 25, 50 or 100 mg. The starting dose of lamotrigine took into account concomitant AEDs ( Table 1 ). The dose was not increased at the end of the second week if the patient experienced any adverse events of clinical significance deemed attributable 
TABLE 1
Recommended dosage regimen of lamotrigine, according to concomitant antiepileptic drug treatment in adults and children
Dose of lamotrigine
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to lamotrigine. Before stopping lamotrigine therapy completely, in the case of withdrawal for any reason, the dose was reduced to 50% for 2 weeks and then to 25% for a further 2 weeks.
ADVERSE EXPERIENCES
Adverse experiences were recorded at each clinic visit. The severity and seriousness were noted, and the investigator gave an assessment of the likelihood that adverse experiences could be attributed to the study drug. Any actions taken were also noted. Serious adverse events (defined as any event that is fatal, life-threatening, severely or permanently disabling, or that requires or prolongs hospitalization) were notified to the study directors immediately.
WITHDRAWALS
Patients were withdrawn from the study if they developed severe or unacceptable adverse experiences, if lack of efficacy or any risk was judged by the investigator to outweigh the benefits from continued lamotrigine treatment, if there was evidence of serious non-compliance, or if they developed other severe illness.
STATISTICAL ANALYSIS
All information for each patient was recorded in a data collection book. Limited statistical analysis was performed because of the open nature of the study.
RESULTS
STUDY POPULATION
A total of 62 patients were enrolled in the study, with 61 patients providing evaluable data for the efficacy analysis. Patients ranged in age from 8 years to 62 years, with a mean age of 31 years. There were 33 males and 28 females in the study from five participating centres. All patients had treatment-resistant epilepsy, with a high frequency of seizures per month. The nature of the epilepsy suffered is detailed in Table 2 , with the epilepsy type specified according to the predominant form of seizures; 41 patients suffered more than one type of seizure. The type of epilepsy was not recorded for two patients. The most common form of epilepsy experienced by the patients in this study was complex partial seizures. Of the 26 patients with this classification as the predominant form, four were classified as Bl (two of subtype Bla, one of subtype Blb and one not specified) and 22 were of form B2 (seven of subtype B2a, 13 of subtype B2b and two not specified).
A total of 13 patients withdrew from the study (four due to lack of efficacy of the study medication, four due to adverse events and five for other reasons).
CONCOMITANT ANTlEPILEPTIC DRUGS
In this heterogenous group of patients, concomitant treatment at the start of the study was with a range of AEDs. Most patients were treated with a combination of carbamazepine and another drug. Nine patients were on monotherapy at the start of the study (six receiving carbamazepine and three treated with valproate alone). 
DOSAGE OF LAMOTRIGINE
OVERALL EFFICACY
Throughout the study a mean of 57% (4B -67%) of patients given lamotrigine. showed improvement, 34% (25 -40%) showed no change and 9% (3 -15%) showed a deterioration (Fig. 1) . The efficacy data are grouped according to seizure type in Table 3 . The differences between the groups were not great and no statistical analysis was done. However, the highest percentage of patients showing improvement (65%) was among those with generalized seizures, and the lowest percentage showing improvement (53%) was among those suffering from complex partial seizures. Table 4 shows the efficacy data grouped according to the initial concomitant AED. The proportion of patients showing improvement was highest among those treated with valproate alone 152 (B3%) and lowest among those treated with carbamazepine alone (34%).
CHANGES IN ANTIEPILEPTIC DRUGS
During the course of the study, the doses of AEDs given to more than half of the patients (34 out of61; 56%) were reduced, and seven patients were able to stop taking one AED entirely. Of the 12 patients receiving carbamazepine with vigabatrin initially, four were able to have an AED dose reduction, though three-quarters (eight patients) did not have the dose of AED adjusted. Among those receiving carbamazepine with valproate, there was an equal split between those having no change of AED (seven patients) and those having a dose reduction (seven).
In contrast, proportionately more of those initially receiving carbamazepine were able to have a reduction in AED (11 of 14 patients). When the seizure type was considered, similar numbers of patients were able to reduce AED levels and had the initial level maintained for all epilepsy categories with the exception of type B complex seizures (10 patients had no change in medication and 16 had AED levels reduced). Proportionately more type C 
ADVERSE EXPERIENCES
The majority of adverse experiences were rated as mild or moderate in intensity, were not serious and did not require treatment.
The most common adverse experiences were tremor (particularly of the right hand), somnolence and dizziness. Although adverse experiences were reported by 75% of patients during the 2 years of the study, there were only four reports of severe adverse events (behavioural disturbance, unsteadiness/nystagmus, aggression and kidney pain/haematuria). There were 25 reports of serious adverse experiences, most commonly somnolence (three reports) and nausea/vomiting (three reports).
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DISCUSSION
The results of this open study were consistent with the efficacy of lamotrigine seen in double-blind, placebo-controlled studies in treatment-resistant epilepsy! - 7 and similar open studies conducted in other countries." - 13 Overall, in this study lasting 2 years, seizure control improved in 57% of these treatment-resistant patients, was unchanged in 34% and deteriorated in 9%. Efficacy was maintained throughout the duration of the study. Likewise, in long-term studies of patients given lamotrigine for up to 5 years, there was no evidence of a loss of efficacy.2:J,24
The patients recruited to this study suffered from a variety of seizure types and the efficacy of lamotrigine in these types was considered. Although statistical analysis was not performed, efficacy appeared to be greatest among patients with predominantly o Leitiio, MJ Sampaio et al,
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generalized seizures (type D), with improvement in 65% of these patients.
Patients suffering complex partial seizures showed the lowest response rate (53%). While no clinical significance may be inferred, it is interesting to note that this trend was consistent with that reported in an Italian study.':' in which 35 of 38 (92%) patients with treatment-resistant generalized epilepsy responded to add-on therapy with lamotrigine over a period of 6 months, compared with a 35% response rate among 69 patients with partial seizures. Pooled results from 27 open studies of lamotrigine as add-on therapy in adults with treatment-resistant epilepsy also found greater efficacy in tonic-elonic seizures (52%) than in partial seizures (28%).7 Although there were considerable variations in the responses seen in these different open studies, this probably reflects differences in the refractoriness of the various study populations. Further, although the trials were of broadly similar design, there may have been differences in admission criteria, the type and length of AED therapy before the trial, the type and number of seizures experienced before the trial, sex and age distributions of patients, and assessment methods. Nevertheless, the trends are apparent and may warrant further investigation.
The reason for the difference in response between epilepsy types is not clear. Striano et alyJ suggested that one reason for the greater efficacy of lamotrigine in generalized epilepsy could be synergy with valproate used in the majority of these patients. This possibility is supported in the present study, which found that efficacy with lamotrigine was highest in patients already taking valproate (83% improvement in three patients taking valproate alone, 65% improvement in 11 patients taking valproate with other AEDs excluding carbamazepine, and 61 % in 14 patients taking valproate with carbamazepine). While patients with type D epilepsy formed a majority of those taking val proate alone (two of three patients) and val proate with non-carbamazepine treatment (six of 11 patients), this was not the case with patients receiving val proate/carbamazepine treatment (two of 14 patients). This suggests that there may be synergy with valproate. Nevertheless, lamotrigine is an effective addon therapy, even to regimens that do not include valproate (e.g. 61% improvement in 12 patients receiving carbamazepine with vigabatrin). The efficacy of lamotrigine add-on therapy seemed to be lowest among the six patients receiving only carbamazepine therapy initially (34% improvement), half of whom suffered from type B seizures (partial epilepsy).
Patients taking high doses of multiple therapies for treatment-resistant epilepsy may face considerable problems from associated side-effects and interactions. A reduction in the dose and number of AEDs, while maintaining or improving seizure control, is highly desirable. In this study, more than half of the patients (56%) were able to reduce their dose of initial AED, with seven able to remove one AED entirely. This confirms the previously reported concept that lamotrigine, as monotherapy or in combination, increases the options available for achieving seizure control in these patients.P-"
Lamotrigine was generally well tolerated. Although three-quarters of patients had at least one adverse experience, most of these events were assessed as mild or moderate, required no treatment and were not judged to be serious. The types of events that were observed in the present study were similar to those reported previously.v" Of the 13 patients withdrawing from the study, only four were due to adverse events.
In conclusion, the results of this study are consistent with other reports that lamotrigine is an effective and well-tolerated add-on therapy for patients with treatment-resistant partial and generalized seizures. o Leitiio, MJ Sampaio et al.
